<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03427593</url>
  </required_header>
  <id_info>
    <org_study_id>6642</org_study_id>
    <nct_id>NCT03427593</nct_id>
  </id_info>
  <brief_title>Severe PID With Lymphoproliferation and Neutropenia</brief_title>
  <acronym>DICEP</acronym>
  <official_title>Phenotype-genotype Correlation in a Sub-population of Severe Primary Immunodeficiency With Lymphoproliferation and Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analyse the phenotype in a sub-population of adults with
      severe primary immunodeficiency with lymphoproliferation and neutropenia and to decipher the
      possible pathways involved, especially under the hypothesis of a CTLA4/LRBA schema
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2018</start_date>
  <completion_date type="Anticipated">March 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of known mutations by target sequencing of all known genes involved in CVID phenotypes.</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
    <description>Target-NGS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of new mutations in new genes in CVID by WES (whole exome sequencing) strategy.</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
    <description>WES (Whole exome sequencing), If no known mutations is founded by T-NGS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation or not of a pathological pathway involving CTLA4/LRBA or a related pathway in T-cells. Validation by the mean of functional analysis of T-cells in vitro of CTLA4 expression and response to stimulation. RNA-sequencing in sorted cells.</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deciphering of new possible genes involved in the phenotype : Patient without known mutation in genes involved in PID will benefit of an extended analyse of the WES to find a possible condidate genes</measure>
    <time_frame>Day 0 (inclusion)</time_frame>
    <description>After WES analyses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Primary Immune-Deficiency (PID) Common Variable Immune Deficiency (CVID)</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with the phenotype (PID and Neutropenia and lymphoproliferation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>relatives (parents)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>FACS analyses</intervention_name>
    <description>FACS analyses</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>relatives (parents)</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Target Sequencing by NGS ( Next-generation sequencing)</intervention_name>
    <description>Target Sequencing by NGS ( Next-generation sequencing)</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>relatives (parents)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Whole Exome Sequencing</intervention_name>
    <description>Whole Exome Sequencing</description>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_label>relatives (parents)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :

          -  &gt;18 years old

          -  CVID (Common Variable Immunodeficiency)

          -  Neutropenia

          -  Lymphoproliferation

        Exclusion Criteria :

        - Secondary immunodeficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aurélien GUFFROY, MD</last_name>
    <phone>33369551223</phone>
    <email>aurelien.guffroy@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne-Sophie KORGANOV</last_name>
    <phone>33369550994</phone>
    <email>anne-sophie.korganow@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Immunologie Clinique et VIH - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien GUFFROY, MD</last_name>
      <phone>0369551223</phone>
      <email>aurelien.guffroy@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Martin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie Korganow, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aurélien GUFFROY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CVID</keyword>
  <keyword>Neutropenia</keyword>
  <keyword>Autoimmunity</keyword>
  <keyword>Lymphoproliferation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

